MedWatch

German drug group hopes to find prize asset with Danish partner

The new collaboration between Danish Gubra and German Boehringer Ingelheim will have immediate positive impact on the Danish contract research organization. Boehringer will have to wait 6-7 years for the results of the partnership but hopes to find a prize asset to compete with, for instance, Novo Nordisk.

The new partnership agreement between Gubra and Boehringer Ingelheim sets more records for the Danish contract research organization (CRO) than the German drug group.

The potential value of the agreement is EUR 240 million (USD 268.6 million), which will without a doubt have a direct and visible impact on Gubra. For Boehringer, this is a smaller sum but the German giant hopes that the agreement will also have positive impact on the bottom line in the long term.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier